Eptinezumab
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Eptinezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Eptinezumab is an anti-CGRP (calcitonin gene-related peptide) monoclonal antibody already used for migraine prevention (episodic and chronic, with or without aura). The TxGNN model predicts it may specifically benefit Migraine with Brainstem Aura, a distinct ICHD-3 subtype, though currently no dedicated clinical trials and only 8 supporting publications (mostly reviews and a post-hoc subgroup analysis) exist for this exact indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (eptinezumab holds no Taiwan license; per known pharmacology it is globally indicated for migraine prevention, episodic and chronic) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L3 |
| Market Status | Not marketed (Taiwan) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal MOA documentation for eptinezumab is currently a data gap. Based on known pharmacology, eptinezumab is an anti-CGRP monoclonal antibody, already approved for migraine prevention regardless of aura status or frequency (episodic vs. chronic). CGRP’s role in the migraine pain-transduction pathway is well established.
However, “migraine with brainstem aura” (formerly basilar-type migraine) is a specific ICHD-3 subtype whose aura component is thought to involve brainstem/cortical spreading depression rather than the peripheral pain pathway that CGRP antibodies primarily target. A 2025 RCT (PMID 40229719) found that PACAP38-induced migraine attacks occur independently of CGRP signaling, suggesting the aura-generating mechanism may have a CGRP-independent component. This is a meaningful mechanistic caveat: efficacy against migraine pain does not guarantee efficacy against this aura subtype specifically.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40229719 | 2025 | RCT | The Journal of Headache and Pain | PACAP38-induced migraine attacks occur independently of CGRP signaling — a mechanistic caveat for aura-specific efficacy |
| 35302389 | 2022 | RCT post-hoc analysis | Cephalalgia | Post-hoc analysis of PROMISE-1/2 evaluating eptinezumab efficacy/safety in patients with self-reported aura |
| 32699706 | 2020 | Review | Cureus | Reviews CGRP antagonists, including eptinezumab, across episodic and chronic migraine |
| 30725283 | 2019 | Review | Handbook of Experimental Pharmacology | Establishes CGRP’s central role in migraine pathophysiology, including aura subgroup |
| 40341526 | 2025 | Review/Cohort | Headache | Case series of genetic migraine disorders responsive to CGRP antagonist therapy |
| 40191903 | 2025 | Case report | Revista de Neurología | Case of eptinezumab managing wearing-off effect in chronic migraine with aura refractory to other CGRP antibodies |
| 33550872 | 2021 | Review | Pain Management | Overview of new acute/preventive migraine therapies including eptinezumab |
| 35268319 | 2022 | Case reports + literature review | Journal of Clinical Medicine | Reviews evidence (sparse) on anti-CGRP mAbs, including eptinezumab, for migraine aura specifically |
Market Information
Eptinezumab is not currently marketed in Taiwan; no NDA or license records are available (0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA label warnings/contraindications retrieval is currently blocked (data gap, high severity), which prevents formal S1 safety screening for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: No trials or literature specifically target the “migraine with brainstem aura” subtype — current evidence is a post-hoc subgroup analysis plus general reviews (L3), and one RCT (PMID 40229719) raises a mechanistic caveat that CGRP-independent pathways may drive aura symptoms. Combined with the drug’s absence from the Taiwan market and a blocking TFDA safety data gap, there is insufficient basis to advance.
To proceed, the following is needed:
- TFDA-equivalent safety label (warnings/contraindications) to clear the S1 safety gate
- Formal DrugBank/manufacturer MOA documentation
- A dedicated trial or prospective subgroup analysis in patients specifically diagnosed with migraine with brainstem aura
- Confirmation of Taiwan market entry pathway/status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.